Market Overview

UPDATE: Stifel Nicolaus Raises PT to $85 on Gilead Sciences on HCV Data

Share:
Related GILD
How To Use Options During Earnings Season
These Were The Most Bought And Sold Stocks In September
Trump Likely To Sign Executive Order On Drug Pricing 'Any Day' (Investor's Business Daily)

Stifel Nicolaus maintained its Buy rating on Gilead Sciences (NASDAQ: GILD) and increased its price target from $80 to $85.

Stifel Nicolaus commented, "Twelve week sofosbuvir plus BMY's NS5a daclatasvir treatment achieved an impressive SVR4 of 98% in treatment naïve genotype 1 patients, and the same combo with ribavirin achieved a 95% SVR4. … On the Abbott investor call held last night, ABT management indicated that they expect data from its six-trial registrational program in 2013 with market launch in 2015."

Gilead Sciences closed at $73.93 on Monday.

Latest Ratings for GILD

DateFirmActionFromTo
Oct 2017BarclaysReinstatesOverweightOverweight
Oct 2017Morgan StanleyMaintainsEqual-Weight
Oct 2017Leerink SwannMaintainsMarket Perform

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (GILD)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...